Study wrapper · #760
Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection.
Editor's note
Here hexarelin is the actual intervention, administered to golden hamsters after optic-nerve transection to test whether it protects retinal ganglion cells. Researchers reported dose-dependent increases in cell survival: single daily doses of 25, 50 and 100 µg/kg raised survival from about 51% (saline) to 62%, 69% and 75% respectively over 7 days, and twice-daily dosing (100 and 150 µg/kg) raised it further, to roughly 91% and 109% of the saline reference. This is a genuine hexarelin signal in a neuroprotection model, consistent with the peptide's described anti-apoptotic activity. Caveats: a single-species rodent model, a narrow survival endpoint, and no functional-vision measures. These are preclinical findings; human data would be needed before any clinical conclusion.
Plain-language abstract
This study tested whether the peptide hexarelin could help retinal nerve cells survive after damage to the optic nerve in hamsters. After the optic nerve was cut, animals received daily injections of hexarelin at different doses for five days, and surviving retinal ganglion cells were counted a week later. Higher single daily doses led to more surviving cells: survival rose from about 51% with salt water to 62%, 69% and 75% at increasing hexarelin doses. Giving hexarelin twice a day boosted survival further, with the highest dose showing the best result. The researchers concluded that hexarelin increased nerve-cell survival in a dose-dependent way, with twice-daily dosing at the higher amount being most protective. This is an early animal study measuring cell survival only, not actual vision, and it does not show what hexarelin does in people.